Compare DexCom, Inc. (DXCM) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

IEFA trades at $96.78, down slightly by 0.11% today, while maintaining a bullish technical signal with strong moving average support. The ETF focuses on developed international equities outside the U.S. and Canada, offering diversification from domestic market concentration. Recent news highlights its role in reducing S&P 500 concentration risk and its competitive 3.30% dividend yield. Technical indicators show neutral oscillators but bullish moving averages, with key support at $96 and resistance at $98.

The outlook for IEFA is positive, driven by international diversification benefits and potential gains if global central bank policies stabilize. Risks include currency fluctuations and political shifts in key markets like the UK. Analyst sentiment is favorable, emphasizing low costs and yield advantages over peers. Investors should weigh geopolitical and economic exposures against diversification gains.